Keryx Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2005, the company has made significant strides in developing innovative therapies for patients with kidney disease, particularly focusing on conditions such as chronic kidney disease and end-stage renal disease. Keryx is best known for its flagship product, Auryxia (ferric citrate), which uniquely addresses both iron deficiency and hyperphosphataemia in patients undergoing dialysis. This dual-action capability sets Keryx apart in a competitive market. With a commitment to improving patient outcomes, Keryx has established a strong market position, recognised for its contributions to renal health. The company continues to expand its operational reach, aiming to enhance the quality of life for patients globally.
We don't have data for Keryx Biopharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company